GCB-27b 

GCB-27b is an immunostimulant that binds to CD1d. GCB-27b forms a stable and long-lasting complex with CD1d, which is presented to the TCR of NKT cells to drive immune responses. GCB-27b induces a Th1-skewed immune response in *Mus musculus*, resulting in high expression of IFN?γ with restricted IL-4 levels. GCB-27b is applicable to research related to lung metastasis of melanoma^[1].

GCB-27b (1-1000 nM; 72 h) potently stimulates Th1-biased cytokine production in C57BL/6 mouse splenocytes in vitro, with no observed cytotoxicity^[1].
GCB-27b (100 nM; 2-24 h) forms more stable and sustained complexes with CD1d on mouse BMDCs in vitro, with enhanced surface presentation relative to αGalCer at 12, 18, and 24 h postincubation^[1].
GCB-27b (24 h) potently induces Th1-biased activation of human PBMC-derived NKT cells in vitro, with a 2-fold higher frequency of IFN-γ⁺ cells relative to αGalCer^[1].
GCB-27b has higher computed binding affinity for both human and murine CD1d than αGalCer, with a docking score of 20 for both, due to optimized hydrophobic interactions in the CD1d A' pocket^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

GCB-27b (2.33 nmol per mouse; i.p.; single dose) induces a 10.5-fold higher serum IFN-γ level than αGalCer in BALB/c mice, with IL-4 levels similar to αGalCer, demonstrating potent Th1-biased immune activity^[1].
GCB-27b (2.33 nmol per mouse; i.p.; single dose) potently activates splenic DCs (via increased CD80 and CD86 expression) and NK cells (via elevated IFN^?γ production) in C57BL/6 mice, demonstrating robust innate immune stimulation^[1].
GCB-27b (0.58 nmol per mouse; i.p.; single dose) reduces B16?F10 melanoma lung metastatic nodule counts by 88% relative to αGalCer in C57BL/6 mice, driven by a potent Th1-biased cytokine response^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

894.31

C₅₂H₉₅NO₁₀

O[C@H]1[C@@H](CO)O[C@H](OC[C@H](NC(CC2=CC=C(OCC(CCCCCCCCC)CCCCCCCCC)C=C2)=O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC)[C@H](O)[C@H]1O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wen Y, et al. Highly Potent Th1-Type NKT Cell Agonists as Immunotherapeutic Agents via Conformational Restriction Design. JACS Au. 2026;6(2):1171-1184. Published 2026 Feb 6.  [Content Brief]